Association of baseline immune cell composition with CAR-T cell expansion and survival in Relapsed/Refractory large B-Cell lymphoma
Xin-di Liu, He-nan Wang, Li-jie Zeng, Yuan-zheng Liang, Fu-li Li, Jin-yan Zhu, Jia Cong, Liang Wang · 2026
Read Association of baseline immune cell composition with CAR-T cell expansion and survival in Relapsed/Refractory large B-Cell lymphoma by Xin-di Liu, He-nan Wang, Li-jie Zeng, Yuan-zheng Liang, Fu-li Li, Jin-yan Zhu, Jia Cong, Liang Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471250.txt.
Description
Liu and a cell therapy team asked in 2026 whether the immune mix in blood before CAR-T therapy predicts how engineered cells behave in relapsed B-cell lymphoma. The study followed 33 patients receiving a dual-target CAR-T product at one center, profiling blood immune subsets before treatment. The cells' growth inside each patient was tracked and grouped into patterns, and survival compared across patterns.
Two growth patterns appeared: eighteen patients showed low expansion, fifteen high expansion with a stronger, later peak, cresting around day 14 instead of day 10. The high group started with more naive and helper T cells, a higher CD4-to-CD8 ratio, and fewer activated regulatory T cells, the immune system's brakes. A higher starting ratio meant longer freedom from progression, risk cut by more than half, though the authors stress the small exploratory sample: these are hypotheses for prospective trials, not clinical rules.
Catalog record
| CREATOR | Xin-di Liu, He-nan Wang, Li-jie Zeng, Yuan-zheng Liang, Fu-li Li, Jin-yan Zhu, Jia Cong, Liang Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |